Novavax (NVAX) Invested Capital (2010 - 2026)

Novavax's Invested Capital history runs 17 years deep, the most recent figure standing at $146.3 million for Q1 2026.

• In Q1 2026, Invested Capital rose 293.38% year-over-year to $146.3 million; the TTM figure through Mar 2026 stood at $146.3 million (up 293.38% YoY), while the FY2025 annual figure was $116.5 million, up 120.68% from the prior year.
• Invested Capital was $146.3 million for Q1 2026 at Novavax, up from $116.5 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $146.3 million in Q1 2026 to a low of -$895.6 million in Q1 2023.
• Historically, Invested Capital has averaged -$406.9 million across 5 years, with a median of -$526.4 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Invested Capital slumped 1470.98% in 2023, then soared 293.38% in 2026.
• A 5-year view of Invested Capital shows it stood at -$634.1 million in 2022, then declined by 13.07% to -$716.9 million in 2023, then climbed by 21.46% to -$563.1 million in 2024, then soared by 120.68% to $116.5 million in 2025, then rose by 25.6% to $146.3 million in 2026.
• The last three Invested Capital figures came in at $146.3 million (Q1 2026), $116.5 million (Q4 2025), and -$156.7 million (Q3 2025), per Business Quant data.